Q-omics provides the consensus-scored OTUD7A profile across patient tissues and cancer cell-line models. OTUD7A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OTUD7A is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, OTUD7A RNA expression shows 18,972 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where OTUD7A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OTUD7A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OTUD7A survival associations across molecular data types. OTUD7A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OTUD7A RNA expression–survival associations across cancer types. High OTUD7A expression shows favorable associations in KIRC, HNSC, SCLC, UVM, PAAD and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for OTUD7A RNA expression.
This table summarizes OTUD7A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for OTUD7A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OTUD7A shows lower tumor expression in COAD, LUAD, BLCA, THCA and UCEC and higher tumor expression in LIHC. The COAD box plot shows higher OTUD7A RNA expression in normal versus tumor tissue (log2 FC = −0.558, t-test p < 0.001).
This table shows molecular features associated with OTUD7A in patient tissues and cancer cell lines. In patient samples, OTUD7A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, OTUD7A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
